Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 49

1.

Health outcomes and unmet needs in patients with long-standing rheumatoid arthritis attending tertiary care in Greece: a cohort study.

Boumpas DT, Sidiropoulos P, Settas L, Szczypa P, Tsekouras V, Hernandez Daly AC.

Health Qual Life Outcomes. 2019 Apr 29;17(1):73. doi: 10.1186/s12955-019-1127-8.

2.

Comparative Analysis and Predictors of 10-year Tumor Necrosis Factor Inhibitors Drug Survival in Patients with Spondyloarthritis: First-year Response Predicts Longterm Drug Persistence.

Flouri ID, Markatseli TE, Boki KA, Papadopoulos I, Skopouli FN, Voulgari PV, Settas L, Zisopoulos D, Iliopoulos A, Geborek P, Drosos AA, Boumpas DT, Sidiropoulos P.

J Rheumatol. 2018 Jun;45(6):785-794. doi: 10.3899/jrheum.170477. Epub 2018 Apr 1.

3.

Longterm Beneficial Effect of Canakinumab in Colchicine-resistant Familial Mediterranean Fever.

Laskari K, Boura P, Dalekos GN, Garyfallos A, Karokis D, Pikazis D, Settas L, Skarantavos G, Tsitsami E, Sfikakis PP.

J Rheumatol. 2017 Jan;44(1):102-109. doi: 10.3899/jrheum.160518. Epub 2016 Nov 15.

PMID:
28042127
4.

Treatment with the first TNF inhibitor in rheumatoid arthritis patients in the Hellenic Registry of Biologic Therapies improves quality of life especially in young patients with better baseline functional status.

Boubouchairopoulou N, Flouri I, Drosos AA, Boki K, Settas L, Zisopoulos D, Skopouli FN, Papadopoulos I, Iliopoulos A, Kyriopoulos J, Boumpas DT, Athanasakis K, Sidiropoulos P.

Clin Exp Rheumatol. 2016 Nov-Dec;34(6):999-1005. Epub 2016 Oct 7.

PMID:
27749220
5.

Safety profile of repeated rituximab cycles in unselected rheumatoid arthritis patients: a long-term, prospective real-life study.

Vassilopoulos D, Delicha EM, Settas L, Andrianakos A, Aslanidis S, Boura P, Katsounaros M, Athanassiou P, Tempos K, Skarantavos G, Antoniadis C, Papazoglou S, Sakkas L, Galanopoulou V, Skopouli F, Boki K, Daoussis D, Vritzali E, Sfikakis PP.

Clin Exp Rheumatol. 2016 Sep-Oct;34(5):893-900. Epub 2016 Jul 5.

6.

Clinical expression and course in patients with late onset systemic lupus erythematosus.

Stefanidou S, Gerodimos C, Benos A, Galanopoulou V, Chatziyannis I, Kanakoudi F, Aslanidis S, Boura P, Sfetsios T, Settas L, Katsounaros M, Papadopoulou D, Giamalis P, Dombros N, Chatzistilianou M, Garyfallos A.

Hippokratia. 2013 Apr;17(2):153-6.

7.

Comparative effectiveness and survival of infliximab, adalimumab, and etanercept for rheumatoid arthritis patients in the Hellenic Registry of Biologics: Low rates of remission and 5-year drug survival.

Flouri I, Markatseli TE, Voulgari PV, Boki KA, Papadopoulos I, Settas L, Zisopoulos D, Skopouli FN, Iliopoulos A, Bertsias GK, Geborek P, Drosos AA, Boumpas DT, Sidiropoulos P.

Semin Arthritis Rheum. 2014 Feb;43(4):447-57. doi: 10.1016/j.semarthrit.2013.07.011. Epub 2013 Sep 6.

PMID:
24012040
8.

Frequency and specificity of antibodies against nuclear and cytoplasmic antigens in healthy individuals by classic and new methods.

Giannouli E, Chatzidimitriou D, Gerou S, Gavriilaki E, Settas L, Diza E.

Clin Rheumatol. 2013 Oct;32(10):1541-6. doi: 10.1007/s10067-013-2284-5. Epub 2013 May 11. No abstract available.

PMID:
23666319
9.

Micro- and macrovascular treatment targets in scleroderma heart disease.

Dimitroulas T, Giannakoulas G, Karvounis H, Garyfallos A, Settas L, Kitas GD.

Curr Pharm Des. 2014;20(4):536-44. Review.

PMID:
23565639
10.

B-type natriuretic peptide in rheumatic diseases: a cardiac biomarker or a sophisticated acute phase reactant?

Dimitroulas T, Giannakoulas G, Karvounis H, Garyfallos A, Settas L, Kitas G.

Autoimmun Rev. 2012 Oct;11(12):837-43. doi: 10.1016/j.autrev.2012.02.018. Epub 2012 Feb 28. Review.

PMID:
22401930
11.

Systemic sclerosis-related pulmonary hypertension: unique characteristics and future treatment targets.

Dimitroulas T, Giannakoulas G, Karvounis H, Settas L, Kitas GD.

Curr Pharm Des. 2012;18(11):1457-64. Review.

PMID:
22364130
12.

Reactivation of occult hepatitis B virus infection, following treatment of refractory rheumatoid arthritis with abatacept.

Germanidis G, Hytiroglou P, Zakalka M, Settas L.

J Hepatol. 2012 Jun;56(6):1420-1. doi: 10.1016/j.jhep.2011.10.011. Epub 2011 Nov 27. No abstract available.

13.

Association of anti-CCP positivity and carriage of TNFRII susceptibility variant with anti-TNF-α response in rheumatoid arthritis.

Vasilopoulos Y, Bagiatis V, Stamatopoulou D, Zisopoulos D, Alexiou I, Sarafidou T, Settas L, Sakkas L, Mamouris Z.

Clin Exp Rheumatol. 2011 Jul-Aug;29(4):701-4. Epub 2011 Sep 1.

PMID:
21813066
14.

Clinical expression and morbidity of systemic lupus erythematosus during a post-diagnostic 5-year follow-up: a male:female comparison.

Stefanidou S, Benos A, Galanopoulou V, Chatziyannis I, Kanakoudi F, Aslanidis S, Boura P, Sfetsios T, Settas L, Katsounaros M, Papadopoulou D, Giamalis P, Dombros N, Chatzistilianou M, Garyfallos A.

Lupus. 2011 Oct;20(10):1090-4. doi: 10.1177/0961203311403640. Epub 2011 Jun 23.

PMID:
21700658
15.

Radionuclide imaging with human polyclonal immunoglobulin (Tc-HIG) and bone scan in patients with rheumatoid arthritis and serum-negative polyarthritis.

Gerasimou G, Moralidis E, Papanastasiou E, Liaros G, Aggelopoulou T, Triantafyllidou E, Lytras N, Settas L, Gotzamani-Psarrakou A.

Hippokratia. 2011 Jan;15(1):37-42.

16.

Biomarkers in systemic sclerosis-related pulmonary arterial hypertension.

Dimitroulas T, Giannakoulas G, Karvounis H, Settas L, Kitas GD.

Curr Vasc Pharmacol. 2011 Mar;9(2):213-9. Review.

PMID:
21143174
17.

Scleroderma renal crisis accompanied by new-onset pulmonary arterial hypertension: an acute systemic endothelial injury? Case report and literature.

Dimitroulas T, Sarafidis P, Roma V, Karagiannopoulou G, Kapoulas S, Dimitroula H, Settas L, Lasaridis A.

Inflamm Allergy Drug Targets. 2010 Sep;9(4):313-8. Erratum in: Inflamm Allergy Drug Targets. 2011 Aug;10(4):310.

PMID:
20969543
18.

Significance of serum uric acid in pulmonary hypertension due to systemic sclerosis: a pilot study.

Dimitroulas T, Giannakoulas G, Dimitroula H, Sfetsios T, Parcharidou D, Karvounis H, Settas L.

Rheumatol Int. 2011 Feb;31(2):263-7. doi: 10.1007/s00296-010-1557-4. Epub 2010 Jul 25.

PMID:
20658290
19.

Left atrial volume and N-terminal pro-B type natriuretic peptide are associated with elevated pulmonary artery pressure in patients with systemic sclerosis.

Dimitroulas T, Giannakoulas G, Papadopoulou K, Sfetsios T, Karvounis H, Dimitroula H, Parcharidou D, Koliakos G, Garyfallos A, Styliadis I, Settas L.

Clin Rheumatol. 2010 Sep;29(9):957-64. doi: 10.1007/s10067-010-1494-3. Epub 2010 Jun 5.

PMID:
20526641
20.

Early detection of cardiac involvement in systemic sclerosis assessed by tissue-Doppler echocardiography: relationship with neurohormonal activation and endothelial dysfunction.

Dimitroulas T, Giannakoulas G, Papadopoulou K, Karvounis H, Dimitroula H, Koliakos G, Karamitsos T, Parcharidou D, Settas L.

J Rheumatol. 2010 May;37(5):993-9. doi: 10.3899/jrheum.090931. Epub 2010 Mar 1.

PMID:
20194451
21.

Paget's disease of the vulva in a patient with scleroderma and underlying adenocarcinoma: case report.

Dimitroulas T, Settas L.

Eur J Gynaecol Oncol. 2009;30(4):458-9.

PMID:
19761147
22.

Natriuretic peptides in systemic sclerosis-related pulmonary arterial hypertension.

Dimitroulas T, Giannakoulas G, Karvounis H, Gatzoulis MA, Settas L.

Semin Arthritis Rheum. 2010 Feb;39(4):278-84. doi: 10.1016/j.semarthrit.2009.03.005. Epub 2009 Jun 17. Review.

PMID:
19539354
23.

Guidelines for initiation of anti-tumour necrosis factor therapy in rheumatoid arthritis: similarities and differences across Europe.

Emery P, Van Vollenhoven R, Ostergaard M, Choy E, Combe B, Graninger W, Krueger K, Matucci-Cerinic M, Navarro F, van Riel P, Settas L, Steinfeld S.

Ann Rheum Dis. 2009 Apr;68(4):456-9. doi: 10.1136/ard.2008.100362. No abstract available. Erratum in: Ann Rheum Dis. 2011 Aug;70(8):1519.

PMID:
19286904
24.

Determination of two COX-2 inhibitors in serum and synovial fluid of patients with inflammatory arthritis by ultra performance liquid chromatography-inductively coupled plasma mass spectroscopy and quadrupole time-of-flight mass spectrometry.

Gika HG, Theodoridou A, Michopoulos F, Theodoridis G, Diza E, Settas L, Nikolaidis P, Smith C, Wilson ID.

J Pharm Biomed Anal. 2009 Apr 5;49(3):579-86. doi: 10.1016/j.jpba.2008.12.006. Epub 2008 Dec 13.

PMID:
19155154
25.

Asymmetrical dimethylarginine in systemic sclerosis-related pulmonary arterial hypertension.

Dimitroulas T, Giannakoulas G, Sfetsios T, Karvounis H, Dimitroula H, Koliakos G, Settas L.

Rheumatology (Oxford). 2008 Nov;47(11):1682-5. doi: 10.1093/rheumatology/ken346. Epub 2008 Aug 27.

PMID:
18753191
26.

N-terminal pro-brain natriuretic peptide in systemic sclerosis related pulmonary arterial hypertension under bosentan treatment.

Dimitroulas T, Giannakoulas G, Karvounis H, Dimitroula H, Settas L.

Rheumatol Int. 2009 Jan;29(3):347-8. doi: 10.1007/s00296-008-0667-8. Epub 2008 Aug 9. No abstract available.

PMID:
18690444
27.

Limitations of the findings regarding the relationship between N-terminal pro-brain natriuretic peptide and systemic sclerosis-related pulmonary arterial hypertension: comment on the article by Allanore et al.

Dimitroulas T, Giannakoulas G, Karvounis H, Settas L.

Arthritis Rheum. 2008 Jul;58(7):2215-6; author reply 2216. doi: 10.1002/art.23588. No abstract available.

28.

Demyelination in rheumatic diseases.

Theodoridou A, Settas L.

Postgrad Med J. 2008 Mar;84(989):127-32. doi: 10.1136/jnnp.2005.075861. Review.

PMID:
18372483
29.

N-terminal probrain natriuretic peptide as a biochemical marker in the evaluation of bosentan treatment in systemic-sclerosis-related pulmonary arterial hypertension.

Dimitroulas T, Giannakoulas G, Karvounis H, Koliakos G, Sfetsios T, Dimitroula H, Settas L.

Clin Rheumatol. 2008 May;27(5):655-8. doi: 10.1007/s10067-007-0828-2. Epub 2008 Jan 18.

PMID:
18204995
30.

Reactivation of pulmonary tuberculosis in a patient with rheumatoid arthritis during treatment with IL-1 receptor antagonists (anakinra).

Settas LD, Tsimirikas G, Vosvotekas G, Triantafyllidou E, Nicolaides P.

J Clin Rheumatol. 2007 Aug;13(4):219-20.

PMID:
17762459
31.

Neurohormonal activation in patients with systemic sclerosis-related pulmonary arterial hypertension.

Dimitroulas T, Giannakoulas G, Karvounis H, Sfetsios T, Koliakos G, Parcharidis G, Settas L.

Int J Cardiol. 2007 Sep 14;121(1):135-7. Epub 2006 Nov 7.

PMID:
17088004
32.

Tuberculosis in patients receiving anti-TNF agents despite chemoprophylaxis.

Sichletidis L, Settas L, Spyratos D, Chloros D, Patakas D.

Int J Tuberc Lung Dis. 2006 Oct;10(10):1127-32.

PMID:
17044206
33.

Etanercept 50 mg once weekly is as effective as 25 mg twice weekly in patients with ankylosing spondylitis.

van der Heijde D, Da Silva JC, Dougados M, Geher P, van der Horst-Bruinsma I, Juanola X, Olivieri I, Raeman F, Settas L, Sieper J, Szechinski J, Walker D, Boussuge MP, Wajdula JS, Paolozzi L, Fatenejad S; Etanercept Study 314 Investigators.

Ann Rheum Dis. 2006 Dec;65(12):1572-7. Epub 2006 Sep 12.

34.

Reversible T-large granular lymphocyte expansion and neutropenia associated with adalimumab therapy.

Theodoridou A, Kartsios C, Yiannaki E, Markala D, Settas L.

Rheumatol Int. 2006 Dec;27(2):201-2. Epub 2006 Aug 25. No abstract available.

PMID:
16932958
35.

Fibromyalgia--new concepts of pathogenesis and treatment.

Lucas HJ, Brauch CM, Settas L, Theoharides TC.

Int J Immunopathol Pharmacol. 2006 Jan-Mar;19(1):5-10. Review.

PMID:
16569342
36.

Demyelination in rheumatic diseases.

Theodoridou A, Settas L.

J Neurol Neurosurg Psychiatry. 2006 Mar;77(3):290-5. Review.

37.

Early T cell activation in the skin from patients with systemic sclerosis.

Kalogerou A, Gelou E, Mountantonakis S, Settas L, Zafiriou E, Sakkas L.

Ann Rheum Dis. 2005 Aug;64(8):1233-5.

38.

Presentation and analysis of data on radiographic outcome in clinical trials: experience from the TEMPO study.

van der Heijde D, Landewé R, Klareskog L, Rodríguez-Valverde V, Settas L, Pedersen R, Fatenejad S.

Arthritis Rheum. 2005 Jan;52(1):49-60.

39.

Efficacy and safety of adalimumab as monotherapy in patients with rheumatoid arthritis for whom previous disease modifying antirheumatic drug treatment has failed.

van de Putte LB, Atkins C, Malaise M, Sany J, Russell AS, van Riel PL, Settas L, Bijlsma JW, Todesco S, Dougados M, Nash P, Emery P, Walter N, Kaul M, Fischkoff S, Kupper H.

Ann Rheum Dis. 2004 May;63(5):508-16.

40.

Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial.

Klareskog L, van der Heijde D, de Jager JP, Gough A, Kalden J, Malaise M, Martín Mola E, Pavelka K, Sany J, Settas L, Wajdula J, Pedersen R, Fatenejad S, Sanda M; TEMPO (Trial of Etanercept and Methotrexate with Radiographic Patient Outcomes) study investigators.

Lancet. 2004 Feb 28;363(9410):675-81.

PMID:
15001324
41.

Effect of sulphasalazine in patients with juvenile chronic arthritis (JCA).

Settas L, Alexiou P, Dimitriadis G, Mata-Tsi E, Souliou E, Papapanagiotou J, Tourkantonis A.

Acta Univ Carol Med (Praha). 1991;37(1-2):76-9. No abstract available.

PMID:
1688267
42.

Lupus anticoagulant--antiphospholipid antibodies and thrombophilia. Relation to protein C--protein S--thrombomodulin.

Tsakiris DA, Settas L, Makris PE, Marbet GA.

J Rheumatol. 1990 Jun;17(6):785-9.

PMID:
2167370
43.

Impaired fibrinolysis as an essential contribution to thrombosis in patients with lupus anticoagulant.

Tsakiris DA, Marbet GA, Makris PE, Settas L, Duckert F.

Thromb Haemost. 1989 Apr 25;61(2):175-7.

PMID:
2501894
44.

Acute psoriatric arthropathy precipitated by oxprenolol.

Macfarlane DG, Settas L.

Ann Rheum Dis. 1984 Feb;43(1):102-4.

45.

Clinical experience with long-term nitrendipine treatment in essential hypertension.

Tourkantonis A, Lasaridis A, Settas L.

J Cardiovasc Pharmacol. 1984;6 Suppl 7:S1090-5.

PMID:
6085373
46.

Kingella kingae causing septic arthritis in Felty's syndrome.

Lewis DA, Settas L.

Postgrad Med J. 1983 Aug;59(694):525-6.

47.

Remission of pseudo-spondylitis with treatment of Whipple's disease.

Bowman C, Dieppe P, Settas L.

Br J Rheumatol. 1983 Aug;22(3):181-2.

PMID:
6191820
48.

Localised chondrocalcinosis in unstable joints.

Settas L, Doherty M, Dieppe P.

Br Med J (Clin Res Ed). 1982 Jul 17;285(6336):175-6. No abstract available.

49.

Haemodialysis and hypothalamo-pituitary-testicular axis.

Tourkantonis A, Spiliopoulos A, Pharmakiotis A, Settas L.

Nephron. 1981;27(4-5):271-2.

PMID:
6791041

Supplemental Content

Loading ...
Support Center